2Kebebew E, ltuarte PH, Siperstein AE, et al. Medullary thyroid carcinoma : clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer, 2000, 88: 1139-1148.
3Scopsi L, Sampietro G, Boracchi P, et al. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer, 1996, 78 : 2173-2183.
4Fuchshuber PR, Loree TR, Hicks WL Jr, et al. Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol, 1998, 5:81-86.
5Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs acalcitonine. Clin Endoerinol ( Oxf), 1998, 48: 265 -273.
6Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologie entity. J Chn Endocrinol Metab, 1959, 19: 152-161.
7Corsello SM, Lovicu RM, Migneco MG, et al. Diagnostic approach, genetic screening and prognostic factors of medullary thyroid carcinoma. Rays, 2000, 25:257-266.
8Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer, 1996, 77 : 1556-1565.
9Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Greupe d' Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab,2000, 85:919-922.
10Scheuba C, Kaserer K, Kotzmann H, et al. Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrinstimulated calcitonin. Thyroid, 2000, 10 : 413-416.
